A Trial to Learn What Happens to Different Medicinal Forms of BAY2328065 When They Enter the Body and How Safe They Are in Healthy Male and Female Participants

  • End date
    Jan 10, 2022
  • participants needed
  • sponsor
Updated on 26 September 2021
body mass index


Researchers are looking for a different way to treat women with a condition in which tissue that normally lines the uterus grows outside the uterus. This condition is called endometriosis. Before a treatment is available to all patients, researchers study it in clinical trials to better understand its safety and what happens to it in the body.

BAY2328065 is being developed to help treat women who have endometriosis. Women with endometriosis often have very painful menstrual periods, as well as pain in the pelvic area which is not related to menstrual periods and pain during intercourse. Many women with endometriosis may also have problems becoming pregnant. The trial treatment, BAY2328065, works by blocking a certain protein that causes pain and swelling of the tissue and is thought to play a role in endometriosis.

In this trial, the researchers want to compare what happens to different medicinal forms of BAY2328065 in the body. They also want to learn if eating a meal affects what happens to BAY2328065 in the body.

This trial will include about 32 men and women who are aged 18 to 55. There will be 4 groups of participants in this trial. The participants in Groups 1, 2, and 3 will be men. The participants in Group 4 will be women. There will be 3 treatment courses to the trial for Groups 1, 2 and 3 and 1 treatment course for Group 4.

During the trial, the participants in Groups 1, 2, and 3 will stay at the trial site for 15 days (3 times 5 days with times in between during which they stay at home). The participants in Group 4 will stay at the trial site for 16 days continuously. But, the trial will last about 6 weeks for the participants in Groups 1, 2, and 3. The trial will last about 9 weeks for the participants in Group 4.

All of the participants in Groups 1 and 2 will take the different medicinal forms of BAY2328065, with and without food. All of the participants in Groups 1 and 2 will take dose "2" of BAY2328065 in all 3 treatment courses. In Group 1, they will take BAY2328065 one time each during the following treatment courses:

  • A medicinal form of BAY2328065 without food in treatment course 1, then
  • A medicinal form of BAY2328065 differing from the one used in treatment course 1 without food in treatment course 2, then
  • The medicinal form of BAY2328065 used in treatment course 1 with food in treatment course 3 The participants in Group 2 will do the same, but they will take each form of BAY2328065 in a different order. Information gathered from Group 1 and 2 will help the researchers learn which form of BAY2328065 will be most suited to give to the participants in Groups 3 and 4.

The participants in Group 3 will take 3 different doses of BAY2328065 with food in each treatment course. They will take one time each during the following treatment courses:

  • Single administration of dose "1" in treatment course 1, then
  • Single administration of dose "2" in treatment course 2, then
  • Single administration of dose "3" in treatment course 3 This will help the researchers learn the safest dose to give to the participants in treatment course 4.

The participants in Group 4 will either take dose "3" or "2" of BAY2328065 based on the results of treatment course 3, or a placebo. A placebo looks like a treatment but does not have any medicine in it. All of the participants will take either:

  • Multiple administrations of dose "3" of BAY2328065 or dose "2" of BAY2328065, OR
  • the placebo The participants will take BAY2328065 or placebo over 12 days and with food.

The doctors/ healthcare staff will:

  • take blood and collect urine samples
  • check the participants' heart health

The participants will:

  • answer questions about how they are feeling
  • say if they have any medical problems
  • say if they have taken any medications

Condition Endometriosis, Female Genital Diseases
Treatment Placebo, BAY2328065
Clinical Study IdentifierNCT04851483
Last Modified on26 September 2021


Yes No Not Sure

Inclusion Criteria

Participant must be 18 to 55 years of age inclusive, at the time of signing the informed consent
Participants must be overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, ECG, blood pressure and heart rate
Confirmation of the subject's health insurance coverage prior to the first screening examination/visit
Body mass index (BMI) within the range 18 and 30 kg/m^2 (inclusive)
Male participants who are sexually active and female participants of childbearing potential must use one of the methods of contraception described in this protocol

Exclusion Criteria

Incompletely cured pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination and effects of the study intervention will not be normal
Relevant diseases within the last 4 weeks prior to start of the first study intervention
Known severe allergies, non-allergic drug reactions, or multiple drug allergies
Existing chronic diseases as specified in protocol
Regular use of therapeutic or recreational drugs
Suspicion of drug or alcohol abuse
Smoking equal or more than 10 cigarettes/day
History of COVID-19; contact with SARS-CoV-2 positive persons or COVID-19 patients within the last 4 weeks prior admission to the ward or positive SARS-CoV-2 viral RNA test
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note